Navigation Links
Sofinnova Ventures Announces Team Expansion and Promotion
Date:5/2/2013

MENLO PARK, Calif., May 2, 2013 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park investment firm, today announced a senior team addition and key promotion. Srinivas Akkaraju , M.D., Ph.D. has joined the firm as General Partner and Anand Mehra , M.D., has been promoted to General Partner.

A long-term investor in the life science sector, Dr. Akkaraju will actively invest in biopharmaceutical companies from the firm's current fund, Sofinnova Venture Partners VIII.  He was most recently a Managing Director at New Leaf Venture Partners. Dr. Akkaraju's board memberships have included Piramed (acquired by Roche), Eyetech Pharmaceuticals (EYET), Synageva BioPharma (GEVA), Seattle Genetics (SGEN) and Intercept Pharmaceuticals (ICPT). Previously, Dr. Akkaraju was a co-founder and Managing Director at Panorama Capital. Before forming Panorama, he served as Partner of J.P. Morgan Partners. Prior to J.P. Morgan Partners, Dr. Akkaraju held business and corporate development positions at Genentech. Dr. Akkaraju received B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine.

Dr. Mehra, who joined Sofinnova as a Principal in 2007 and was later promoted to Partner, has now been promoted to General Partner. He led Sofinnova's investment in Vicept Therapeutics (Acquired: Allergan), and served as Sofinnova's most recent board member at NextWave Pharmaceuticals (Acquired: Pfizer). He also played a role in the firm's investments in Hyperion (HPTX) and Amarin (AMRN). Currently, Dr. Mehra is a director of Aerie Pharmaceuticals and Marinus Pharmaceuticals, and led the firm's recent investment in Aclaris.

"We are pleased to have the opportunity to both attract proven talent and recognize excellent work within our team. We have known Srini for many years, as a colleague and an investor. His outstanding track record in private and public companies, coupled with a deep background in clinical drug development, make him a valued addition to our team," commented Jim Healy , M.D., Ph.D., General Partner at Sofinnova Ventures.

"Anand has been a contributing member of this team since the day he joined us," continued Healy. "His analytical skills, critical thinking and deep network of relationships have helped us make great investment decisions and driven value for our management teams and limited partners. As General Partners, Srini and Anand will help us continue to build our portfolio of industry-leading biotech companies."

"I have great respect for the Sofinnova Ventures team, and I'm excited to be joining this partnership," said Akkaraju. "Sofinnova has emerged as one of the key leaders in life sciences investing, developing an exceptional portfolio and delivering excellent results for their investors. I am looking forward to contributing to the firm's continued success."  

In the past year, three Sofinnova portfolio companies have completed IPOs (Durata, Nasdaq: DRTX; Hyperion, Nasdaq: HPTX and Kalobios, Nasdaq: KBIO). The firm has also made public investments in Amarin (AMRN) and TESARO (TSRO). Recent portfolio acquisitions include SARcode (Shire), NextWave (Pfizer), IntelliKine (Takeda), Vicept (Allergan), Preglem ( Gedeon Richter ) and Movetis (Shire).

About Sofinnova Ventures

Sofinnova Ventures has over 40 years of experience building healthcare companies into market leaders. With $1.4 billion in committed capital, the firm applies capital and expertise to take companies from inception to exit. Sofinnova closed its life science-focused $440M fund, SVP VIII, in late 2011. The firm's investment team of M.Ds. and Ph.Ds. has significant scientific, operational and strategic experience, and specializes in financing later stage clinical products and growth companies. Our team partners with entrepreneurs to address patients' unmet medical needs. Recent portfolio company exits and IPOs include Preglem, Movetis, Vicept, NextWave, Hyperion (IPO) and Durata (IPO). Sofinnova Ventures has offices in Menlo Park and La Jolla, California, and Dublin, Ireland. For more information, please visit www.sofinnova.com.

Media Contact:
Jennifer James
VP, Investor Relations & Marketing
Sofinnova Ventures
(650) 681-8429
jennifer@sofinnova.com


'/>"/>
SOURCE Sofinnova Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Leonhardt Ventures to Present Technology Showcase @ Heart Rhythm 2013
2. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
3. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
4. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
5. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
6. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
7. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
8. Sunpeaks Ventures Announces Second Quarter 2012 Results
9. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
10. Pappas Ventures Names Pat Gage to Scientific Advisory Board
11. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
Breaking Medicine News(10 mins):